Results 61 to 70 of about 6,976 (185)

Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 3, February 2026.
This systematic review and meta‐analysis (100 trials, 9192 patients) clarifies breast cancer ICI‐based combination toxicity hierarchies. ICI‐ADC has higher grade ≥ 3 TRAEs; ICI‐mTKI has the worst irAEs, while ICI‐PARPi/HER2‐targeted combinations present the lowest risks.
Yunwei Lu, Huan Li, Ke Li, Yiting Chen, Shu Wang   +4 more
wiley   +1 more source

Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review

Frontiers in Pharmacology
Trastuzumab deruxtecan (T-DXd or DS-8201), as a novel antibody–drug conjugate, has demonstrated good efficacy in HER2-positive advanced breast cancer.
Simin Luo, Jie Chai, Linxiaoxiao Ding, Song Tang   +3 more
doaj   +1 more source

Efficacy and safety of different drugs in patients with HER2-positive gastric cancer: network meta-analysis

Systematic Reviews
Background In the past decade, there has been a significant advancement in targeted therapy and immunotherapy, leading to the discovery of new drugs and changes in the treatment approach for patients with HER2-positive gastric cancer.
Jie Zhang, Chunluan Yuan, Xiao Ma
doaj   +1 more source

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States

Breast Cancer: Targets and Therapy, 2022
Yitian Lang,1 Bin Wu,2 Xiaoyan Liu1 1Department of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Medical Decision and Economic Group, Department of ...
Lang Y, Wu B, Liu X
doaj  

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report

, 2023
Benita Wolf, Vincent Dunet, Estelle Dubruc, Ana Dolcan, Marie Nicod Lalonde, Luis Schiappacasse, Khalil Zaman   +6 more
openalex   +1 more source

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report

International Journal of Women's Health
Yuanping Chen,1 Chao Liu,1 Xinglin Wen,2 Chen Wang,1 Jing He1 1Department of Oncology, Ganzhou People’s Hospital, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, People’s Republic of China; 2Department of Medical Image, Ganzhou People’s ...
Chen Y, Liu C, Wen X, Wang C, He J
doaj  

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Cancer Reports
Background Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2‐positive breast cancer. Recent studies have also highlighted the presence of activating mutations in HER2, and HER3 that are ...
Page E. Blas, Esther San Roman Rodriguez, Heather L. Williams, Maren K. Levin, Joshua S. K. Bell, Mariaelena Pierobon, Alexander S. Barrett, Emanuel F. Petricoin, Joyce A. O'Shaughnessy   +8 more
doaj   +1 more source

Severe Anti-HER2 Drug-induced Interstitial Lung Disease: A Report of Two Cases and Clinical Implications

Xiehe Yixue Zazhi
Human epidermal growth factor receptor 2 (HER2) is a key therapeutic target for breast cancer. With the wide application of anti-HER2 and HER2 antibody-drug conjugates such as trastuzumab, pertuzumab, trastuzumab emtansine, and trastuzumab deruxtecan ...
SHEN Zhu, FAN Dandan, CHEN Lei, CHEN Guangqiang, WANG Yanan, HU Zhanhong, PAN Jie, GENG Zhou   +7 more
doaj   +1 more source

Trastuzumab-deruxtecan in breast cancer treatment: Balancing the triad of efficacy, safety and accessibility

Annals, Academy of Medicine, Singapore
Trastuzumab deruxtecan (T-DXd), an anti-human epidermal growth receptor 2 (HER2) antibody-drug conjugate (ADC), has emerged as a transformative therapy for metastatic breast cancer (MBC), demonstrating efficacy across the full spectrum of HER2 ...
Victor Guan Hui Lee, Joline Si Jing Lim
doaj   +1 more source

Concurrent trastuzumab deruxtecan-induced interstitial lung disease and COVID-19 in the treatment of advanced breast cancer [PDF]

, 2023
Naoaki Yasuda, Satoshi Ikeo, Akihiko Sokai, Yuki Sakai, Yasuyuki Hayashi, Sae Kitano, Naoko Itoi, Tecchuu Lee, Toshiyuki Iwata, Takashi Nishimura   +9 more
openalex   +1 more source